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Poster Session I S267Results: Disease status (relapse/refractory, CR2, or CR3) did not
have a significant effect on disease-free survival (p 5 0.75). Clonal
evolution, however, did have a significant negative impact on dis-
ease-free survival (p 5 0.03). Day 100 disease free survival was
50% versus 100% for patients with and without clonal evolution, re-
spectively. Similarly, one year disease-free survival was 20% and
83% for patients with and without clonal evolution. Among the pa-
tients with clonal evolution, there was no significant difference in
disease-free survival between patients with only one new cytogenetic
abnormality and those with more than one new cytogenetic abnor-
mality (p 5 0.19).
Conclusion: Clonal evolution appears to identify a very high-risk
group of patients who may benefit from novel transplant strategies
and post-HSCT interventions. Future studies should seek to validate
these findings in a multi-institutional setting.310
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Allogeneic haematopoietic stem cell transplant (AlloHSCT) in
children is associated with serious complications. Hypertension
(HT) is reported to occur in 21-63% of adult HSCT patients.
Data on the incidence of HT in children undergoing HSCT are lim-
ited.
Objectives: To establish the incidence of and identify the risk fac-
tors associated with the development of HT in pediatric AlloHSCT
patients and to determine the duration and impact of HT on cardiac
function at one year and overall survival (OS).
Methods: We conducted a retrospective study of all children who
underwent AlloHSCT at The Hospital for Sick Children from
2004 to 2007 and were followed in Toronto or Halifax. Demo-
graphic information, underlying diagnosis, conditioning regimen,
GvHD prophylaxis, blood pressure, GvHD, survival, medication
history and echocardiography results were collected in the first
year post HSCT.
Results: 172 children (59% male; mean age 5 8.46 years; range
0.25-18 years) underwent AlloHSCT during the study period.
67% had an underlying malignant disease; 83% received myeloabla-
tive conditioning and 45% received total body irradiation. 93% re-
ceived cyclosporine for GVHD prophylaxis, most commonly in
combination with methotrexate (78%). Stem cell donors were: living
related donor (LRD) in 51%; living unrelated donor (LURD) in
33% and unrelated cord in 16%.
111/172 (65%) developed HT in the first 100 days after Al-
loHSCT.Childrenwithmalignant disease were less likely to develop
HT compared to children without a malignancy (p\ 0.008). Chil-
dren who had a non-cord HSCT and developed GVHD were
more likely to develop HT (p 5 0.045). Gender, age and condition-
ing regimen were not associated with HT. 36/149 (24%) evaluable
children were hypertensive at D+90, 16/138 (12%) at D+180 and
5/126 (4%) at one year. No child had ventricular dysfunction (mea-
sured by echo) at one year. A total of 46 patients had died by one year
post transplant. HT did not influence OS at one year after Al-
loHSCT (p 5 0.37).
Conclusions:HToccurs commonly post AlloHSCT in children but
usually resolves by one year post transplant. HT did not lead to car-
diac impairment or influence OS at one year.311
SIGNATURE PROFILES OF CMV-SPECIFIC T-CELLS IN PEDIATRIC PA-
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and University Hospital Motol, Prague, Czech RepublicDepletion of cellular immunity as a consequence of condition-
ing before allogeneic hematopoietic stem cell transplantation fre-
quently results in CMV reactivation, which may in turn lead to
life-threatening infections and require timely antiviral treatment.
We have investigated the functional signatures of CMV-specific
CD4+ and CD8+ T-cells in 191 samples from 118 individuals.
We included patients with either high or undetectable viral loads,
and those who controlled or did not control their CMV reactiva-
tions. All patient subsets were compared to healthy donors. Poly-
chromatic flow cytometric measurements of CD154 (CD40L),
intracellular cytokines (IFNg, IL2), and a degranulation marker
(CD107a) revealed the functional status of various T-cells simul-
taneously. We found that dual IFNg/IL2 producing CD8+
T-cells were significantly decreased in patients non-controlling
their CMV reactivations compared to controllers. In contrast,
CD8+ T-cells that produced IFNg only were the most abundant
subtype but they were present in a substantial number of non-
controllers. Hierarchical clustering of distinct functional signa-
tures revealed that polyfunctional CD8+ T-cells were acting in
concert with other subsets, whereas the isolated production of
IFNg by CD8+ T cells heralds insufficient collaboration with
others. In conclusion, our study revealed functional signatures
that may be useful for immune monitoring, and they may change
the interpretation of previous studies that assessed only IFNg.
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Background: Adenoviral (AdV) infections are a major cause of mor-
bidity and mortality in hematopoietic stem cell transplant (HSCT)
patients (pts). Quantitative molecular detection of AdV using poly-
merase chain reaction (PCR) has recently becomemore widely avail-
able in the clinical setting for early detection and monitoring of AdV
infection, although challenges regarding interpretation of results and
implications for treatment remain.
Methods:Weperformed a retrospective cohort study of all pediatric
HSCT pts who underwent AdV PCR testing from May 2008
through April 2010. Clinical characteristics of AdV-positive (POS)
pts were compared to AdV-negative (NEG) pts.
Results: Of 48 pts with AdV testing, 43 had complete transplant
records and were included in the analysis. Seven (16.3%) pts were
AdV-POS. Overall pt characteristics were comparable between
the two groups. The following medication exposures were identi-
fied as risk factors influencing AdV status: preparatory regimens
utilizing fludarabine (Relative Risk [RR] 8.73, 95% Confidence
Interval [CI]: 1.18-64.27, p 0.006), melphelan (RR 3.47, 95%
CI 0.76-15.94, p 0.08), and/or cyclophosphamide (RR 0.18,
95% CI 0.02-1.4, p 0.05), and GVHD prophylaxis with methyl-
prednisone (RR 3.73, 95% CI 1.01-13.9, p 0.04). AdV-POS pts
had higher GVHD grades with higher rates of GVHD of the gas-
trointestinal tract (RR 4, 95% CI 1.18-13.5, p 0.03) compared to
AdV-NEG pts. Amongst seven AdV-POS pts, 57.1% had con-
comitant clinical manifestations of disease including: pneumonia,
diarrhea, and/or disseminated disease. Clinical outcomes in four
symptomatic pts included resolution of disease (2) and death (2),
although one pt had concomitant bacterial sepsis. An additional
AdV–POS pt had prolonged marrow suppression as a probable
clinical manifestation of AdV disease and recovered. All AdV-
POS pts received antiviral therapy, including one pt with severe
disseminated disease that resolved following administration of li-
posomal cidofovir.
Conclusion:Our study at a large pediatric HSCT transplant cen-
ter confirms previously identified risk factors for AdV infection in
previous small studies in adults and children. This study provides
important preliminary data for the design of a prospective trial
which aims to identify specific HCST patient populations who
